Skip to main content

Table 2 Summary of means (± SD) of electrocardiographic examination variables

From: Safety evaluation of the interchangeable use of robenacoxib in commercially-available tablets and solution for injection in cats

Variable

Study phase

Control

1X

2X

3X

Heart Rate [beats/minute]

baseline

288.8 ± 27.4

306.1 ± 20.4

304.0 ± 24.5

306.6 1± 7.2

post-treatment

293.8 ± 42.0

259.8 ± 55.8

267.5 ± 24.8

277.4 ± 25.0

RR Interval [ms]

baseline

209.5 ± 20.8

196.8 ± 13.1

198.7 ± 17.3

196.4 ± 11.5

post-treatment

209.0 ± 37.1

240.6 ± 51.5

226.1 ± 22.2

217.8 ± 19.6

QT Interval [ms]*

baseline

147.4 ± 12.1

139.4 ± 10.8

140.2 ± 12.1

138.9 ± 8.3

post-treatment

143.1 ± 14.5

162.1 ± 25.7

160.2 ± 11.6

162.4 ± 13.7

  1. *significant treatment effect (p=0.02)